Preclinical Study of a Dual-Target Molecular Probe Labeled with 68Ga Targeting SSTR2 and FAP
2024

New Dual-Target Molecular Probe for Tumor Imaging

Sample size: 9 publication 10 minutes Evidence: moderate

Author Information

Author(s): Huanhuan Liu, Xiaojun Zhang, Yue Pan, Jingfeng Zhang, Hui Wen, Cong Zhang, Xiaodan Xu, Guangyu Ma, Ruimin Wang, Jinming Zhang, Gerald Reischl

Primary Institution: Department of Nuclear Medicine, First Medical Center, Chinese PLA General Hospital, Beijing, China

Hypothesis

Can a dual-target molecular probe improve tumor uptake and retention compared to monomeric probes?

Conclusion

The dual-target tracer [68Ga]Ga-TATE-46 improves tumor uptake and retention compared to single-target tracers.

Supporting Evidence

  • [68Ga]Ga-TATE-46 showed higher uptake in SSTR2/FAP-positive tumors compared to monomeric probes.
  • The dual-targeting strategy enhances tumor targeting efficiency.
  • Immunohistochemistry confirmed high expression of SSTR2 and FAP in target tumors.
  • Biodistribution studies indicated effective accumulation of the probe in tumor regions.
  • Blocking experiments demonstrated the specificity of [68Ga]Ga-TATE-46 for its targets.

Takeaway

Scientists created a new probe that can find tumors better by targeting two different markers at once instead of just one.

Methodology

The study involved designing and synthesizing a dual-target probe, testing its binding properties and tumor targeting in vitro and in vivo using specific cell lines and mouse models.

Limitations

The probe showed high uptake in non-target organs like the kidneys, which may limit its therapeutic applications.

Participant Demographics

Female BALB/c nude mice, approximately 3–4 weeks old.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3390/ph17121647

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication